Allantoin Emulsion Stability for Inflammatory Skin Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory skin conditions, such as epidermolysis bullosa and psoriasis, face challenges in stability and effectiveness, particularly with allantoin-based formulations that degrade quickly at room temperature and struggle to provide long-lasting relief from symptoms like inflammation and blistering.
Innovation Solution
Formulations comprising an oil-in-water emulsion with allantoin, combined with excipients like cetyl alcohol, stearyl alcohol, sodium lauryl sulfate, citric acid, lanolin oil, propylene glycol, tetrasodium EDTA, cod liver oil, butylated hydroxytoluene, methylparaben, and propylparaben, which enhance stability and absorption, providing sustained relief for inflammatory skin conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allantoin-based formulations are used to treat inflammatory skin conditions, then effectiveness in reducing symptoms is improved, but stability at room temperature deteriorates due to quick degradation
Solution Approach 1:
The patent uses an oil-in-water emulsion system as an intermediary carrier to protect allantoin from degradation. The emulsion comprises oil phase (containing allantoin), water phase, and emulsifying agents that stabilize the formulation at room temperature, preventing direct exposure of allantoin to degrading environmental factors while maintaining its therapeutic effectiveness.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the formulation by controlling pH (using citric acid to maintain acidic environment), temperature (room temperature stability), and composition ratios (oil-to-water phase ratio, emulsifier concentration) to optimize both stability and effectiveness of allantoin in the emulsion system.
2Ease of manufacture
If simple allantoin formulations are used, then ease of manufacture is improved, but duration of action deteriorates due to quick degradation and inability to provide long-lasting relief
Solution Approach 1:
The patent creates a composite emulsion formulation combining multiple components: allantoin (active ingredient), oil phase (emollients like lanolin oil, cod liver oil), water phase, emulsifying agents (cetyl alcohol, stearyl alcohol, sodium lauryl sulfate), and stabilizers (propylene glycol, EDTA). This composite structure provides both manufacturability and extended duration of action through sustained release and stability.
3Ease of operation
If conventional formulations are used, then application simplicity is improved, but absorption across skin barrier deteriorates due to poor penetration
Solution Approach 1:
The oil-in-water emulsion structure creates a porous-like delivery system where allantoin is distributed throughout the emulsion matrix, allowing gradual release and penetration through skin barrier. The emulsion droplets facilitate transdermal delivery by exploiting skin's natural pathways, enhancing absorption while maintaining simple topical application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations demonstrate improved stability at room temperature, maintaining effectiveness for up to 4 to 10 years and enhanced absorption of allantoin across the skin barrier, leading to significant reduction in symptoms like inflammation, blistering, and scarring.
Implementation Method 1
Formulations comprising an oil-in-water emulsion with allantoin, combined with excipients like cetyl alcohol, stearyl alcohol, sodium lauryl sulfate
Implementation Method 2
enhanced absorption of allantoin across the skin barrier, leading to significant reduction in symptoms
Data Source
AI summary
Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof. Symptoms treated may include pain, inflammation, redness, itching, scarring, skin thickening, milia, or a combination thereof.